Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
Status:
Terminated
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This phase I/randomized phase II trial is studying the side effects and best dose of
bevacizumab and to see how well it works when given together with or without MEDI-522 in
treating patients with unresectable or metastatic kidney cancer. Monoclonal antibodies, such
as bevacizumab and MEDI-522, can block tumor growth in different ways. Some block the ability
of tumor cells to grow and spread. Others find tumor cells and help kill them or carry
tumor-killing substances to them. Bevacizumab and MEDI-522 may also stop the growth of tumor
cells by blocking blood flow to the tumor. It is not yet known whether bevacizumab is more
effective when given together with or without MEDI-522 in treating kidney cancer.